Placental corticotrophin releasing factor may modulate human parturition.
The interactions of corticotrophin releasing factor (CRF) and oxytocin on myometrial contractility were studied in isolated gestational myometrium in vitro. Acting alone oxytocin showed a significant dose related inotropic effect (P less than 0.001), whereas CRF did not. Dose-response curves of oxytocin in the presence of a fixed dose of CRF showed a threefold increase in the response to oxytocin without CRF present (P = 0.0019). When this combined priming and potentiating effect was investigated separately, priming of the myometrial strips with CRF prior to stimulation with oxytocin significantly enhanced the inotropic effect of oxytocin (P = 0.01) and when given together a significant potentiating effect was seen (P = 0.008). It is suggested that placental CRF may act as an important modulator of the inotropic effect of oxytocin on myometrium. The interaction between the two peptides may be similar to that which occurs between CRF and vasopressin in the anterior pituitary gland.
Quartero
H W
HW
Department of Gynaecology, UMDS, London, UK.
Fry
C H
CH
D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology / Q000502:physiology*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007743:Labor, Obstetric / Q000502:physiology*; D010121:Oxytocin / Q000494:pharmacology; D010920:Placenta / Q000502:physiology*; D011247:Pregnancy; D014590:Uterine Contraction / Q000187:drug effects
D010121:Oxytocin; D003346:Corticotropin-Releasing Hormone